JP2024525780A5 - - Google Patents

Info

Publication number
JP2024525780A5
JP2024525780A5 JP2024501976A JP2024501976A JP2024525780A5 JP 2024525780 A5 JP2024525780 A5 JP 2024525780A5 JP 2024501976 A JP2024501976 A JP 2024501976A JP 2024501976 A JP2024501976 A JP 2024501976A JP 2024525780 A5 JP2024525780 A5 JP 2024525780A5
Authority
JP
Japan
Prior art keywords
interleukin
receptor
inhibitor
residue
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024501976A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525780A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/037221 external-priority patent/WO2023288028A2/en
Publication of JP2024525780A publication Critical patent/JP2024525780A/ja
Publication of JP2024525780A5 publication Critical patent/JP2024525780A5/ja
Pending legal-status Critical Current

Links

JP2024501976A 2021-07-14 2022-07-14 インターロイキン-23受容体のペプチド阻害剤 Pending JP2024525780A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163221806P 2021-07-14 2021-07-14
US63/221,806 2021-07-14
PCT/US2022/037221 WO2023288028A2 (en) 2021-07-14 2022-07-14 Peptide inhibitors of interleukin-23 receptor

Publications (2)

Publication Number Publication Date
JP2024525780A JP2024525780A (ja) 2024-07-12
JP2024525780A5 true JP2024525780A5 (cg-RX-API-DMAC7.html) 2025-07-24

Family

ID=84920532

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024501976A Pending JP2024525780A (ja) 2021-07-14 2022-07-14 インターロイキン-23受容体のペプチド阻害剤

Country Status (11)

Country Link
US (1) US20240409598A1 (cg-RX-API-DMAC7.html)
EP (1) EP4370531A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024525780A (cg-RX-API-DMAC7.html)
KR (1) KR20240034222A (cg-RX-API-DMAC7.html)
CN (1) CN117999274A (cg-RX-API-DMAC7.html)
AU (1) AU2022310354A1 (cg-RX-API-DMAC7.html)
CA (1) CA3226539A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024000762A (cg-RX-API-DMAC7.html)
TW (1) TW202332683A (cg-RX-API-DMAC7.html)
UY (1) UY39856A (cg-RX-API-DMAC7.html)
WO (1) WO2023288028A2 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
CA2949215C (en) 2014-05-16 2023-03-14 Protagonist Therapeutics, Inc. .alpha.4.beta.7 integrin thioether peptide antagonists
SG10201810154WA (en) 2014-07-17 2018-12-28 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
WO2018022937A1 (en) 2016-07-27 2018-02-01 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
MX2022008740A (es) 2020-01-15 2022-09-23 Janssen Biotech Inc Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
AU2021383828A1 (en) 2020-11-20 2023-07-06 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
KR20240034224A (ko) 2021-07-14 2024-03-13 얀센 바이오테크 인코포레이티드 인터류킨-23 수용체의 지질화된 펩티드 억제제
EP4652179A1 (en) * 2023-01-16 2025-11-26 Janssen Pharmaceutica NV Lipidated peptide inhibitors of interleukin-23 receptor
EP4652180A2 (en) * 2023-01-16 2025-11-26 Janssen Pharmaceutica NV Peptide inhibitors of interleukin-23 receptor
TW202440615A (zh) * 2023-01-16 2024-10-16 比利時商健生藥品公司 介白素-23受體之肽抑制劑
KR20250139359A (ko) * 2023-01-31 2025-09-23 얀센 파마슈티카 엔브이 인터류킨-23 수용체의 결정질 펩티드 억제제의 제조 방법
AU2024233524A1 (en) * 2023-03-03 2025-10-16 Janssen Pharmaceutica Nv Interleukin-23 receptor antagonist peptides for use in the treatment of psoriasis
EP4471048A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
EP4471049A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
CN121794283A (zh) 2023-09-08 2026-04-03 赛诺菲 作为选择性il-23受体抑制剂的新型肽
CN121909205A (zh) 2023-09-08 2026-04-21 赛诺菲 作为选择性il-23受体抑制剂的新型肽
WO2026013260A1 (en) 2024-07-12 2026-01-15 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2026026816A1 (zh) * 2024-07-30 2026-02-05 西藏海思科制药有限公司 白介素-23受体的肽抑制剂及其用途
WO2026041110A1 (zh) * 2024-08-22 2026-02-26 上海瀚辰星泰医药科技有限公司 一种多肽化合物及其应用
WO2026046292A1 (zh) * 2024-08-28 2026-03-05 西藏海思科制药有限公司 白介素-23受体的肽抑制剂的药物组合物及其制备方法和用途
WO2026138829A1 (zh) * 2024-12-23 2026-07-02 上海医药集团股份有限公司 多肽抑制剂及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9605027B2 (en) * 2011-06-14 2017-03-28 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
SG10201810154WA (en) * 2014-07-17 2018-12-28 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
HK1257747A1 (zh) * 2015-07-15 2019-10-25 Protagonist Therapeutics Inc. 白细胞介素-23受体的肽抑制剂以及其治疗炎症性疾病的用途
US10787490B2 (en) * 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP2020505352A (ja) * 2017-01-18 2020-02-20 プロタゴニスト セラピューティクス, インコーポレイテッド インターロイキン−23受容体のペプチド阻害剤および炎症性疾患を治療するためのそれらの使用
CA3104418A1 (en) * 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2020311395A1 (en) * 2019-07-10 2022-02-03 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
SMT202500254T1 (it) * 2020-01-15 2025-09-12 Janssen Biotech Inc Inibitori peptidici del recettore dell'interleuchina-23 e loro uso per trattare malattie infiammatorie

Similar Documents

Publication Publication Date Title
JP2024525732A5 (cg-RX-API-DMAC7.html)
JP2024525723A5 (cg-RX-API-DMAC7.html)
JP2022540154A5 (cg-RX-API-DMAC7.html)
KR101899803B1 (ko) 소듐 (2r,5s,13ar)-7,9-디옥소-10-((2,4,6-트리플루오로벤질)카르바모일)-2,3,4,5,7,9,13,13a-옥타히드로-2,5-메타노피리도[1',2':4,5]피라지노[2,1-b][1,3]옥사제핀-8-올레이트
JP6606692B2 (ja) (2R,5S,13AR)−8−ヒドロキシ−7,9−ジオキソ−N−(2,4,6−トリフルオロベンジル)−2,3,4,5,7,9,13,13A−オクタヒドロ−2,5−メタノピリド[1’,2’:4,5]ピラジノ[2,1−b][1,3]オキサゼピン−10−カルボキサミドの結晶形
US11634418B2 (en) Amino acid compounds and methods of use
US20220135513A1 (en) Methods of manufacturing treprostinil and treprostinil derivative prodrugs
EP3962602A1 (en) Itaconic acid derivatives and uses thereof in treating an inflammatory disease or a disease associated with an undesirable immune response
JP2025134806A5 (cg-RX-API-DMAC7.html)
CN1104238C (zh) 霉酚酸盐的包有肠溶衣的药物组合物
TW202332683A (zh) 介白素-23受體之肽抑制劑
US10703731B2 (en) Process for the preparation of Trisodium (4- {[1S,3R)-1-([1,1′-biphenyl]-4-ylmethyl)-4-ethoxy-3-methyl-4-oxobutyl]amino}-4-oxobutanoate)-(N-petanoyl-N-{[2′-(1H-tetrazol-1-1D-5-yl)[1,1′-biphenyl]-4-yl]methyl}- L-valinate) and its polymorphs thereof
JP2023504184A5 (cg-RX-API-DMAC7.html)
JP2023511551A5 (cg-RX-API-DMAC7.html)
CN115066418A (zh) 具有抗炎性质的羧基衍生物
CN102264694B (zh) 用于制备伏立诺他的方法
JP5345065B2 (ja) デプシペプチドおよびその治療的使用
EP4237408A1 (en) Itaconic acid derivatives
JP2023513658A5 (cg-RX-API-DMAC7.html)
JP2014511844A5 (cg-RX-API-DMAC7.html)
WO2022090714A1 (en) Novel compounds
JP2012516883A (ja) アクタガルジン誘導体
JP2019519478A (ja) ペプチド−オリゴ尿素フォルダマー化合物及びそれらの使用方法
JP2026503110A (ja) インターロイキン-23受容体の脂質付加ペプチド阻害剤の製剤
JP2012524775A5 (cg-RX-API-DMAC7.html)